Shilpa Medicare Ltd (SML) is the smallcap pharma that behaves like a biotech VC. Market cap = ₹7,548 Cr. CMP = ₹772. P/E = 58.7x — basically, more expensive than Cipla’s inhalers but with half the oxygen.
Quarterly sales ₹321 Cr (up 9.9%), PAT ₹47 Cr (up 234% — base effect ka magic). ROE just 4.2%, ROCE 7.8% — but promoters pledge 7.9% shares. Dividend yield: 0.06% — enough to buy one Disprin strip after taxes.
2. Introduction
Founded in 1987, Shilpa started as an API shop in Raichur and today dreams of becoming India’s Genentech (without the Silicon Valley coffee).
Oncology APIs are their bread-and-butter, supplying to USA, EU, Japan, and other regulators who send inspection letters more regularly than Diwali greetings. They also run contract development & manufacturing (CDMO), biosimilars, oral thin films, transdermal patches, biologics, and even trauma sprays like Dr. Clot (for battlefield bleeding — because why not?).
But financial reality check: sales CAGR 5-10%, profits yo-yoing like Sensex on budget day, debt ₹588 Cr, and working capital cycle at 350 days. Yes, 350. That’s longer than some Netflix series.
Question for you: Is Shilpa a pharma manufacturer or a science project incubator funded by investors’ patience?
3. Business Model – WTF Do They Even Do?
They’ve got more verticals than a South Indian thali:
Formulations: 29% revenue. Injectables, oral solids, oral disintegrating films (yes, tablets that vanish in your mouth faster than your SIP returns).
Biologics & Biosimilars: 11 biosimilars + 1 new biological entity. Basically, the pharma version of lottery tickets.
ODFs & Patches: Their Hyderabad & Bengaluru facilities churn out thin films & transdermals. Think Durex for medicines.
CDMO: Manufacturing for Japan, Spain, and others. Good margins, but scale? TBD.
They also love joint ventures — from Saudi Arabia facilities (70:30 JV with PPI) to Sun Pharma tie-ups for Humira biosimilar (ORIADALI).
Auditor Roast: It’s like they threw darts at a pharma textbook — “oncology, biosimilars, films, patches, sprays” — and decided to do all of it.
4. Financials Overview
Metric
Latest Qtr (Jun’25)
YoY (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
321
293
331
9.9%
-3%
EBITDA
91
70
77
30%
18%
PAT
47
14
15
234%
213%
EPS (₹)
4.8
1.4
1.5
234%
213%
Commentary: Revenue growth = okay. EBITDA = improving. PAT = base-effect glow up. But P/E 59x for 11% topline growth? That’s like paying BMW rates for a Maruti engine swap.
5. Valuation Discussion – Fair Value Range
Method 1: P/E
Annualized EPS (TTM) = ₹11.4.
Assign 25x (laggard pharma) to 40x (growth optimism).
